 As part of a European post-marketing commitment, GSK will conduct a survey of physicians and patients understanding of the significant risks associated with TrobaltTM retigabine, as described in the Patient Information Leaflet PIL and the Physicians Guide. The goal of the surveys is to evaluate the effectiveness of the educational plan as specified in the European Risk Management Plan RMP. 